INTRODUCTION 5 8
Influenza A viruses (IAV) are enveloped viruses with segmented, negative-sense single-stranded RNA 1 1 3 exquisitely sensitive to eIF2α phosphorylation and ternary complex depletion. We have also shown that 1 1 4 IAV mRNAs are sensitive to pateamine A (PatA) (11), a natural product that selectively inhibits the 1 1 5 DEAD-box RNA helicase eIF4A which assembles with eIF4E and eIF4G, to form the eIF4F complex 1 1 6 (13, 14) . By disrupting eIF4A, PatA prevents scanning by the 43S pre-initiation complex, causing arrest 1 1 7 of translation initiation, and inducing SG formation (15) . Specifically, treatment with PatA caused SG In addition to PatA, eIF4A can be inhibited by a variety of natural compounds currently being 1 2 0 investigated for anti-cancer properties, including hippuristanol (16), 15-deoxy-delta 12,14-1 2 1 prostaglandin J2 (15d-PGJ2) (17), silvestrol (18) and synthetic derivatives. Accumulating evidence 1 2 2 indicates that many viruses are highly dependent on eIF4A activity for protein synthesis. For example, 1 2 3 PatA has been shown to limit human cytomegalovirus infection (19) , whereas silvestrol has been shown In this study, we methodically documented the antiviral properties of PatA and silvestrol in three 1 2 6 workhorse models of IAV infection; A549 human lung adenocarcinoma cells, Madin-Darby canine 1 2 7 kidney (MDCK) cells, and African green monkey kidney epithelial cells (Vero) . In all cases, dosages of 1 2 8
PatA and silvestrol sufficient to elicit SGs concurrently blocked viral protein accumulation and genome 1 2 9
replication. PatA, known to bind irreversibly to eIF4A, could sustain long-term arrest of viral protein 1 3 0 synthesis following drug withdrawal, whereas the effects of silvestrol were reversible. Finally, PatA could 1 3 1 inhibit genetically-divergent strains, suggesting common dependence on eIF4A. with infection medium containing 0.5% bovine serum albumin (BSA) in DMEM and incubated at 37˚C in 1 5 0 5% CO2 atmosphere. IAV virions were enumerated by plaque assay using 1.2% Avicel RC 591 (FMC 1 5 1 Corporation) overlay on confluent MDCK cells as described in (21). Where indicated, mock and virus-1 5 2 infected cells were treated with 0.156-40 nM pateamine A or 2.5-640 nM silvestrol. Cells were seeded 24 h before drug treatment at a density of 10,000 cells/well in 96-well plates. Drugs were serially-diluted in media to the indicated concentrations and added to cells. After 24-h treatment, 1 5 7 9 AlamarBlue assay (Thermo Scientific) was conducted according to manufacturer's protocol using Tecan For immunofluorescence microscopy cells grown on glass coverslips were fixed and stained as described Hoechst dye. Images were captured using Zeiss Axioplan II microscope or Zeiss LSM 510 laser scanning (BioRad) and analyzed using goat polyclonal antibody to influenza virus described above (recognizes 1 7 0 HA1, NP, and M1 proteins), mouse monoclonal antibodies to influenza NS1 (clone 13D8, reference (22)), Total RNA was isolated using the RNeasy Plus Mini kit (Qiagen) according to manufacturer's protocol. Viral genomic and messenger RNAs were reverse-transcribed as described in (2) Reverse Transcriptase (Thermo Scientific) in separate reactions containing the gene-specific primer for 1 7 8 18S rRNA (5'-AGG GCC TCA CTA AAC CAT CC-3') and either the influenza A virus-specific 1 7 9 universal primer Uni12 (5'-AGC AAA AGC AGG-3', for vRNA) or the oligo(dT) 18 primer (for mRNA). We previously demonstrated that IAV was sensitive to pharmacologic induction of translation arrest and 1 8 9 SG formation in the early stages of infection (11). To gain a fuller understanding of how eIF4A-targeting 1 9 0 drugs can trigger SG formation and disrupt viral replication, IAV-infected A549, Vero and MDCK cells 1 9 1 were treated at 1 hpi with increasing doses of PatA and silvestrol. In all three cell lines, PatA triggered SG 1 9 2 formation and inhibited IAV protein accumulation at concentrations above 2.5 nM ( Fig. 1A-D ). By Previously, we demonstrated that 10 nM PatA blocked IAV replication in A549 cells through sustained 2 0 0 total protein synthesis arrest and SG formation (11). To further test the effects of PatA and silvestrol on 2 0 1 infectious virus release in the three most common cell culture models of IAV infection, we treated A549, 2 0 2 Vero and MDCK cells with increasing concentrations of these drugs at 1 h post-infection with the PR8 2 0 3 strain of IAV. At 24 hpi, culture supernatants were harvested and the infectious virus titers were 2 0 4 determined using plaque assays in MDCK cells ( Fig. 2A, B ). In agreement with results presented in inhibiting infectious virus release;16-times higher drug concentration was required to match the inhibition 2 0 8 1 2 of infectious virion release observed in A549 cells. Overall, these results reveal tight correlation between 2 0 9 viral protein accumulation and the infectious virus production in these cell lines, and the unexpected 2 1 0 remarkable resistance of Vero cells to silvestrol. Next, we tested the effects of PatA and silvestrol on cell 2 1 1 viability after 24 h treatment using the AlamarBlue assay (Fig. 2C, D) . Both drugs exhibited notable 2 1 2 cytotoxicity at the concentrations required for maximal inhibition of virus replication. However, the 2 1 3 cytotoxic effects varied significantly between the cell lines tested. 5 nM PatA had little effect on A549 2 1 4 cells, but it caused a sharp decrease in viability of MDCK cells. By contrast, among the three cell types, 2 1 5 A549 cells were most sensitive to silvestrol. Taken altogether, these results suggest that PatA is more 2 1 6 effective than silvestrol at inhibiting virus replication at sub-cytotoxic concentrations and exhibits a 2 1 7 narrow therapeutic index in A549 cells. washed off of some infected cells, and SG formation and viral protein accumulation were analyzed using 2 2 8 immunofluorescence microscopy at 12 hpi (Fig. 3A) . Consistent with our previous observations (11), 2 2 9 after withdrawal of PatA, SGs persisted for the remainder of the time-course, and viral proteins did not 2 3 0 accumulate beyond the levels observed at 1 hpi. However, silvestrol withdrawal at 4 hpi led to SG were visualized by western blot (Fig. 3B) . Both silvestrol and PatA caused strong inhibition of protein 2 3 6 synthesis at 1 h post-treatment, which was sustained throughout the 24 h treatment time-couse. Silvestrol 2 3 7 withdrawal at 3 h allowed for a complete restoration of protein synthesis at later times (Fig. 3B, lanes 7 2 3 8 and 12). By contrast, protein synthesis was never restored following PatA wash-off (Fig. 3B , lanes 8 and 2 3 9 13). Together, these findings demonstrate that IAV is able to recover from transient drug-induced 2 4 0 translation arrest and resume the viral replication cycle when eIF4A inhibition is relieved. infected cells in our system, both infected and uninfected A549 cells were treated with 300 nM silvestrol 2 4 8 or 30 nM PatA, and apoptosis was measured by immunoblotting for PARP cleavage products. Following formation, resulting in apoptosis (Fig. 4A, lanes 5-8) . Interestingly, the sustained translation arrest by 2 5 2 silvestrol not only diminished viral protein accumulation, but also prevented the RdRp from switching 2 5 3 tasks between viral mRNA synthesis and genome replication (Fig. 4B ). This finding is consistent with our 2 5 4 1 4 previous observations for PatA (11) , suggesting that both drugs affect the viral replication cycle in the 2 5 5 same way. This dysregulated RdRp activity and an inability to produce the viral PKR antagonist NS1 due 2 5 6 to translation arrest, enables detection of viral pathogen-associated molecular patterns (PAMPs), resulting 2 5 7 in eIF2α phosphorylation (Fig. 4, lanes 5-6) . We have determined that the lab-adapted H1N1 PR8 strain used in this study, which is the preferred 2 6 1 backbone for vaccine production worldwide, is sensitive to eIF4A inhibition. To determine whether a 2 6 2 genetically-divergent IAV strain could be similarly affected by eIF4A inhibiting drugs, A549 cells were synthesis to viral genome replication tasks (Fig. 5A, B) due to failure to accumulate viral proteins (Fig.   2  6  7 5C). Our findings to date indicate that PatA is better than silvestrol at inhibiting PR8 replication at sub-2 6 8 cytotoxic doses. For this reason, we investigated the effects of PatA on release of Udorn from A549 cells. We observed a similar magnitude of inhibition of Udorn virion production in cells treated with low 2 7 0 nanomolar doses of PatA. IAV mRNAs generally resemble host mRNAs, which enables efficient translation by host cell machinery. However, these features also make them susceptible to stress-induced arrest of protein synthesis. Host 2 7 4 translation initiation requires eIF4A, a helicase that unwinds mRNA secondary structure to permit ternary 2 7 5 complex scanning for translation initiation codons. Here, we showed that IAV translation is sensitive to mRNA synthesis to viral genome replication. Both molecules could block replication of genetically-2 8 0 divergent IAV strains, PR8 and Udorn, suggesting a potential universal dependence on eIF4A activity. While the effects of silvestrol were reversible, PatA, known to bind irreversibly to eIF4A, sustained long-2 8 2 term arrest of viral protein synthesis following drug withdrawal. Because many oncogenes have structured 5'-UTRs, and depend on eIF4A activity for their synthesis, murine models (32). Indeed, PatA was able to inhibit oncogene synthesis at low doses that did not 2 8 8 impinge on bulk protein synthesis rates, demonstrating that mRNA structure plays a crucial role in 2 8 9
Our results and previous studies indicate that eIF4A helicase activity is required for translation initiation 3 0 0 on IAV mRNAs, but it appears that processive unwinding of long, structured 5'-UTRs is not required. Consistent with this model, IAV infection was shown to deplete the eIF4A processivity factor eIF4B (36). The virus replicates efficiently in eIF4B-depleted cells, and likely benefits from diminished synthesis of 3 0 3 eIF4B-dependent interferon-stimulated genes like IFITM3. Viral mRNP complexes likely lack eIF4B, but 3 0 4 remain only partially characterized. They have properties that distinguish them from host mRNPs. For 3 0 5 example, there is some evidence that eIF4E1 is also dispensable for viral mRNA translation (37). Moreover, IAV NS1 is known to stimulate viral mRNA translation, which may be linked to its ability to played by eIF4A and other core translation factors. Beyond these considerations of mRNP composition, 3 1 0 dependence on eIF4A helicase activity might also be influenced by host shutoff, which is expected to 3 1 1 markedly influence the availability of host translation factors. We previously established that SGs do not form at any point during IAV infection (10), and that three 3 1 4 viral proteins can inhibit SG formation (11) . We also demonstrated that an early window of opportunity 3 1 5 exists, before sufficient quantities of SG antagonizing viral proteins accumulate, when the virus is 3 1 6 exquisitely sensitive to stress-induced translation arrest. Here, we further elucidated the mechanism of Throughout our studies, SG formation in infected cells reliably indicated disruption of viral protein 3 2 0 accumulation and viral replication (10, 11) . In this study, we observed that, upon withdrawal of silvestrol, demonstrated that PKR is recruited to SGs by direct interaction with G3BP, and that this recruitment results in PKR activation (39, 40) . We observe eIF2α phosphorylation in infected cells after prolonged 3 2 5 SG induction by PatA or silvestrol. It will be interesting to determine whether this phosphorylation is 3 2 6 dependent on PKR activation. Our results show the magnitude of the threat that host-targeted translation inhibitors pose for viral 3 2 9
replication. Nevertheless, the eIF4A inhibitors studied here have some undesirable properties that may be 3 3 0 difficult to surmount. We observed that eIF4A inhibition resulted in cytotoxic effects that largely tracked and -III) are highly conserved between these species. Interestingly, while silvestrol has been shown to 3 3 5 bind to eIF4A-I and eIF4A-II, PatA has been shown to bind to all three isoforms, including eIF4A-III (32, thus has no role in translation initiation. Instead, it is a member of the exon junction complex deposited 3 3 8 on mRNA post-splicing, where it has been shown to participate in nonsense mediated decay (44). Moreover, eIF4AIII was previously shown to interact with the IAV polymerase complex (45). The PatA to its antiviral effects remain to be determined. There is an outstanding need for new antivirals for influenza. Past history has shown that direct-acting are an attractive alternative approach that should limit the emergence of drug-resistant variants. RNA 3 4 6 silencing screens have shown that influenza virus replication depends on thousands of host genes, some of 3 4 7 which may be potential candidates for therapeutic intervention. Our data indicates that inhibition of viral 3 4 8 protein synthesis potently disrupts the viral replication cycle, and drugs that can block viral protein 3 4 9 synthesis may serve as attractive candidates for host-directed antivirals. Despite their antiviral activity 3 5 0 against IAV at high doses, PatA and silvestrol appear to lack specificity for viral translation complexes, viruses (e.g. Ebola, HCMV) and from cancer models, which were shown to be exquisitely sensitive to 3 5 3 much lower doses of eIF4A inhibitor. For these reasons, an effective host-targeted antiviral translation 3 5 4
inhibitor for influenza will ideally be specific for infected cells, while sparing uninfected cells. Alternatively, a detailed characterization of IAV mRNP complexes could highlight unique features that
